Table 2 Study population: clinical features

Male (n, %)

189 (72.9%)

88 (79.2)

101 (68.2)

ns

Age (Median, IQR)

39 (29–71)

39 (29–71)

41 (29–70)

ns

Country of origin (n, %)

 European

107 (41.4)

55 (49.6)

52 (49)

 Immigrant

140 (54)

52 (46.8)

88 (46.5)

 Visitors from endemic country

12 (4.6)

4 (3.6)

8 (4.5)

ns

Comorbidities (n, %)

48 (18.5%)

26 (23.4%)

22 (14.8)

Antimalarial chemoprophylaxis (n, %)

244 (94.2%)

9 (8.1)

6 (4)

ns

Area of infection (n, %):

West Africa

174 (67.1%)

86 (77.4)

88 (59.4)

ns

Purpose of travel (n, %)

 VRFs

83 (32%)

36 (32.4)

47 (31.7)

 Tourism

47 (18.2%)

31 (27.9)

16 (10.8)

 Business

53 (20.4%)

22 (19.8)

31 (20.9)

 Humanitarian aid

28 (10.8%)

13 (11.8)

15 (10.2)

 Other

48 (18.6)

9 (8.1)

39 (26.4)

ns

Plasmodium (n, %)

Falciparum

203 (78.3%)

102 (91.9)

101 (68.3)

 Vivax

38 (14.7%)

6 (5.4)

32 (21.7)

 Ovale

10 (3.9%)

1 (0.9)

9 (6)

 Malariae

3 (1.2%)

0

3 (2)

 Knowlesi

0

0

0

 Mixed Infection

5 (1.9)

2 (1.8)

3 (2)

ns

Delay of diagnosis (Median, IQR) (days)

2 (1–33)

2 (1–33)

2 (1–30)

ns

Delay of treatment (Median, IQR) (days)

3 (2–33)

3 (2–33)

3 (2–31)

ns

Days of hospitalization (Median, IQR) (days)

5 (4–75)

7 (5–75)

5 (4–19)

0.001

Basal % parasitaemia (Median, IQR)(days)

3 ± 2.7

5 ± 3

2 ± 1

ns

Time to parasitaemia < 1% (hours) (M ± SD)

37 ± 22.7

50 ± 27

28 ± 22

0.004

Time to parasite clearance (hours) (M ± SD)

58 ± 39.2

84 ± 45

39 ± 11

0.005

Antimalarial treatment

 Artesunate (iv)

36 (13.9)

25 (22.5)

11 (7.5)

ns

 Quinine (iv)

26 (10)

25 (22.5)

1 (0.7)

 Artemetehr

19 (7.3)

12 (10.8)

7 (4.7)

 Quinine (oral)

20 (7.7)

14 (12.6)

6 (4.1)

 Dihydroartemisinin/piperaquine

125 (48.3)

32 (28.9)

93 (62.8)

 Chloroquine

33 (12.8)

3 (2.7)

30 (20.2)